

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT SELECTION RESULTS OF NATIONAL CENTRALISED MEDICINES PROCUREMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that, a total of 13 products with 16 specifications of the Group submitted for the twelve batch of the National Centralised Medicines Procurement (全國藥品集中採購) in China were all selected in the respective tender results as follows: Blonanserin Tablets (4mg), Betahistine Mesylate Tablets (6mg), Vitamin B₆ Injection (1ml:0.1g), Acipimox Capsules (0.25g), Doxazosin Mesylate Extended Release Tablets (4mg), Bisoprolol Fumarate and Amlodipine Besilate Tablets (bisoprolol fumarate 5mg and amlodipine besilate 5mg), Perindopril Arginine and Amlodipine Besilate Tablets (III) (perindopril arginine 10mg and amlodipine besilate 5mg), Nicardipine Hydrochloride Injection (10ml:10mg) and Nicardipine Hydrochloride Sodium Chloride Injection (200ml: nicardipine hydrochloride 20mg and sodium chloride 1.72g), Bumetanide Injection (2ml: 1mg and 1ml: 0.5mg), Pentoxifylline Sustained-release Tablets (0.4g), Deferasirox Dispersible Tablets (125mg), Composite Potassium Hydrogen Phosphate Injection (5ml: potassium dihydrogen phosphate 1.12g dipotassium hydrogen orthophosphate 1.18g and 2ml: potassium dihydrogen phosphate 0.448g dipotassium hydrogen orthophosphate 0.472g), and Calcium Chloride Injection (10ml: 1g).

The National Centralised Medicines Procurement has brought significant development opportunities to the Group. The Group actively adapts to the policy direction of centralised procurement, focuses on increasing market share of the products, leverages on the advantages of integration of “Bulk Pharmaceuticals + Preparations” and large-scale production, effectively controls the production costs, continuously supplies high-quality products, and constantly strengthens our market competitiveness.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 3 August 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.